首页> 外文期刊>Heart >Hypoalbuminaemia predicts outcome in adult patients with congenital heart disease
【24h】

Hypoalbuminaemia predicts outcome in adult patients with congenital heart disease

机译:低白蛋白血症可预测成年先天性心脏病患者的预后

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background In patients with acquired heart failure, hypoalbuminaemia is associated with increased risk of death. The prevalence of hypoproteinaemia and hypoalbuminaemia and their relation to outcome in adult patients with congenital heart disease (ACHD) remains, however, unknown. Methods Data on patients with ACHD who underwent blood testing in our centre within the last 14 years were collected. The relation between laboratory, clinical or demographic parameters at baseline and mortality was assessed using Cox proportional hazards regression analysis. Results A total of 2886 patients with ACHD were included. Mean age was 33.3 years (23.6-44.7) and 50.1% patients were men. Median plasma albumin concentration was 41.0 g/L (38.0-44.0), whereas hypoalbuminaemia (<35 g/L) was present in 13.9% of patients. The prevalence of hypoalbuminaemia was significantly higher in patients with great complexity ACHD (18.2%) compared with patients with moderate (11.3%) or simple ACHD lesions (12.1%, p<0.001). During a median follow-up of 5.7 years (3.3-9.6), 327 (11.3%) patients died. On univariable Cox regression analysis, hypoalbuminaemia was a strong predictor of outcome (HR 3.37, 95% CI 2.67 to 4.25, p<0.0001). On multivariable Cox regression, after adjusting for age, sodium and creatinine concentration, liver dysfunction, functional class and disease complexity, hypoalbuminaemia remained a significant predictor of death. Conclusions Hypoalbuminaemia is common in patients with ACHD and is associated with a threefold increased risk of risk of death. Hypoalbuminaemia, therefore, should be included in risk-stratification algorithms as it may assist management decisions and timing of interventions in the growing ACHD population.
机译:背景技术在获得性心力衰竭患者中,低白蛋白血症与死亡风险增加相关。成人先天性心脏病(ACHD)患者的低蛋白血症和低蛋白血症的患病率及其与预后的关系仍然未知。方法收集过去14年来在我中心接受血液检查的ACHD患者的数据。使用Cox比例风险回归分析评估基线时实验室,临床或人口统计学参数与死亡率之间的关系。结果共纳入2886例ACHD患者。平均年龄为33.3岁(23.6-44.7),男性为50.1%。血浆白蛋白浓度的中位数为41.0 g / L(38.0-44.0),而13.9%的患者存在低白蛋白血症(<35 g / L)。具有高度复杂性ACHD的患者低白蛋白血症的患病率(18.2%)比具有中度(11.3%)或单纯ACHD病变的患者(12.1%,p <0.001)高得多。在5.7年(3.3-9.6)的中位随访期间,有327名(11.3%)患者死亡。在单变量Cox回归分析中,低白蛋白血症是结果的重要预测指标(HR 3.37,95%CI 2.67至4.25,p <0.0001)。关于多变量Cox回归,在校正年龄,钠和肌酐浓度,肝功能障碍,功能类别和疾病复杂性之后,低白蛋白血症仍然是死亡的重要预测指标。结论低蛋白血症是ACHD患者的常见病,其死亡风险增加了三倍。因此,应将低白蛋白血症纳入风险分层算法中,因为它可能有助于不断增长的ACHD人群的管理决策和干预时机。

著录项

  • 来源
    《Heart》 |2015年第9期|699-705|共7页
  • 作者单位

    Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK,NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College London, London, UK,National Heart and Lung Institute, Imperial College School of Medicine, London, UK,Department of Cardiology and Angiology, Adult Congenital and Valvular Heart Disease Center, University Hospital of Munster, Muenster, Germany,Adult Congenital Heart Centre, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, SW3 6NP London, UK;

    Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK,NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College London, London, UK,National Heart and Lung Institute, Imperial College School of Medicine, London, UK,Department of Cardiology and Angiology, Adult Congenital and Valvular Heart Disease Center, University Hospital of Munster, Muenster, Germany;

    Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK,NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College London, London, UK,National Heart and Lung Institute, Imperial College School of Medicine, London, UK;

    Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK,NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College London, London, UK,National Heart and Lung Institute, Imperial College School of Medicine, London, UK;

    Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK,NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College London, London, UK;

    Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK,NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College London, London, UK,National Heart and Lung Institute, Imperial College School of Medicine, London, UK;

    Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK,NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College London, London, UK,National Heart and Lung Institute, Imperial College School of Medicine, London, UK;

    Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK,NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College London, London, UK,National Heart and Lung Institute, Imperial College School of Medicine, London, UK;

    Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK,NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College London, London, UK,National Heart and Lung Institute, Imperial College School of Medicine, London, UK;

    Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK,NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College London, London, UK,National Heart and Lung Institute, Imperial College School of Medicine, London, UK;

    Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK,NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College London, London, UK,National Heart and Lung Institute, Imperial College School of Medicine, London, UK;

    Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK,NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College London, London, UK,National Heart and Lung Institute, Imperial College School of Medicine, London, UK;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号